Shanghai Junshi Says JS001 Subcutaneous Injection Meets Goal of Late-Stage Study

MT Newswires Live11-25

Shanghai Junshi Biosciences (HKG:1877) said a subcutaneous injection version of its JS001 cancer medicine worked as well as the regular injection version as a first-line treatment of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.

Shares of the healthcare company gained over 5% in morning trade Tuesday.

Results from a late-stage study showed that JS001sc was non-inferior to JS001, or toripalimab, with comparable efficacy and safety profiles in treating recurrent or

metastatic non-squamous non-small cell lung cancer, meeting the main goal of a late-stage study called JS001sc-002-III-NSCLC.

The firm said it planned to submit a new drug application for the subcutaneous injection version of the drug with regulatory authorities in the near future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586445692?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 12:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586445692","market":"sh","top_or_hot":-1,"title":"Shanghai Junshi Says JS001 Subcutaneous Injection Meets Goal of Late-Stage Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a> (HKG:1877) said a subcutaneous injection version of its JS001 cancer medicine worked as well as the regular injection version as a first-line treatment of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.</p><p>Shares of the healthcare company gained over 5% in morning trade Tuesday.</p><p>Results from a late-stage study showed that JS001sc was non-inferior to JS001, or toripalimab, with comparable efficacy and safety profiles in treating recurrent or</p><p>metastatic non-squamous non-small cell lung cancer, meeting the main goal of a late-stage study called JS001sc-002-III-NSCLC.</p><p>The firm said it planned to submit a new drug application for the subcutaneous injection version of the drug with regulatory authorities in the near future.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Junshi Says JS001 Subcutaneous Injection Meets Goal of Late-Stage Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Junshi Says JS001 Subcutaneous Injection Meets Goal of Late-Stage Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-25 12:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a> (HKG:1877) said a subcutaneous injection version of its JS001 cancer medicine worked as well as the regular injection version as a first-line treatment of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.</p><p>Shares of the healthcare company gained over 5% in morning trade Tuesday.</p><p>Results from a late-stage study showed that JS001sc was non-inferior to JS001, or toripalimab, with comparable efficacy and safety profiles in treating recurrent or</p><p>metastatic non-squamous non-small cell lung cancer, meeting the main goal of a late-stage study called JS001sc-002-III-NSCLC.</p><p>The firm said it planned to submit a new drug application for the subcutaneous injection version of the drug with regulatory authorities in the near future.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2586445692","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586445692","pubTimestamp":1764044067,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Junshi Biosciences  said a subcutaneous injection version of its JS001 cancer medicine worked as well as the regular injection version as a first-line treatment of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.Shares of the healthcare company gained over 5% in morning trade Tuesday.Results from a late-stage study showed that JS001sc was non-inferior to JS001, or toripalimab, with comparable efficacy and safety profiles in treating recurrent ormetastatic non-squamous non-small cell lung cancer, meeting the main goal of a late-stage study called JS001sc-002-III-NSCLC.The firm said it planned to submit a new drug application for the subcutaneous injection version of the drug with regulatory authorities in the near future.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","SSI":"Stage Stores Inc","01877":"君实生物","BK1583":"高瓴概念","BK1515":"抗疫概念"},"translate_title":"上海君实称JS001皮下注射达到后期研究目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSI":1.5,"01877":1},"content_text":"Shanghai Junshi Biosciences (HKG:1877) said a subcutaneous injection version of its JS001 cancer medicine worked as well as the regular injection version as a first-line treatment of non-small cell lung cancer, according to a Hong Kong bourse filing Monday.Shares of the healthcare company gained over 5% in morning trade Tuesday.Results from a late-stage study showed that JS001sc was non-inferior to JS001, or toripalimab, with comparable efficacy and safety profiles in treating recurrent ormetastatic non-squamous non-small cell lung cancer, meeting the main goal of a late-stage study called JS001sc-002-III-NSCLC.The firm said it planned to submit a new drug application for the subcutaneous injection version of the drug with regulatory authorities in the near future.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586445692","isCrawlerRequest":true}